logo

丹麦医药市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

丹麦医药市场按 ATC/治疗类别、部门和处方类型细分

Home Industry Reports Healthcare 丹麦医药市场 - 增长、趋势、COVID-19 影响和预测（2022 - 2027 年）

市场快照

Denmark Pharmaceutical Market Overview
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 3.4 %
Denmark Pharmaceutical Market Major players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

丹麦的制药业以提供优质药品和医疗产品而闻名于世。此外，该国拥有庞大的制药和生物技术产业基地，有多家国内公司研究和制造医药产品。还观察到制药行业的营业额在过去十年中有所增加，并且在过去四年中稳步增长。在丹麦，大部分药品支出用于处方药。药店是全国药品销售的主要渠道，近四分之三的营业额来自处方药。

丹麦最大的制药公司是诺和诺德，其次是总部设在该国的另外两家大型制药公司是 H. Lundbeck 和 Leo Pharma。

报告范围

根据本报告的范围，药品分为处方药和非处方药。这些药物可以由个人购买，无论是否有医生的处方，无论是否征得医生的同意，都可以安全地用于各种疾病。该报告还涵盖了对定性和定量数据的深入分析。

By ATC/Therapeutic Class (Both Value and Volume)
Alimentary Tract and Metabolism
Blood and Blood Forming Organs
Cardiovascular System
Dermatological Drugs
Genitourinary System and Reproductive Hormones
Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin
Antiinfectives for Systemic Use
Antineoplastic and Immunomodulating Agents
Musculoskeletal System
Nervous System
Antiparasitic Products, Insecticides and Repellents
Respiratory System
Sensory Organs
Various ATC Structures
By Sector
Primary Sector
Hospital Sector
By Prescription Type
Prescription Drugs (Rx)
OTC Drugs

Report scope can be customized per your requirements. Click here.

主要市场趋势

丹麦医疗保健支出

丹麦的医疗保健支出预计将在未来几年增长。根据经合组织 2015 年公布的数据，丹麦当前的医疗保健支出总额为 46.745 亿美元，2018 年这一数字增加到 52.988 亿美元。在丹麦，控制医疗保健支出的框架在预算法中进行了概述，它为地区和市政府制定预算，并在超出预算时指定自动制裁。此外，通过国家指导方针和临床监测结合集体采购来控制住院药品支出。而药品的采购是通过招标进行的。制药公司每月向丹麦卫生局报告价格表，

此外，根据世界银行在丹麦的估计，2017 年医药支出占卫生支出的 6.3%。医疗支出的增加预计将扩大该国的医药市场。

Denmark Pharmaceutical Market Trends

处方药 (Rx) 占丹麦药品总销售额的最大份额

在丹麦，这些处方不在公共医疗保险范围内。但是，国家计划确实报销了某些药物的部分费用。此外，在丹麦，严格的立法允许直接面向消费者的处方药广告。这对市场产生了积极影响，因为大多数药剂师和最终用户都将非常了解可用于治疗疾病的新药或现有药物。由于慢性病、老年人口和医疗保健支出的增加，处方药的销售额与往年相比有所增加。

Denmark Pharmaceutical Market Share

竞争格局

制药行业竞争激烈，由丹麦的几个主要参与者组成，主要专注于研发。该国的一些主要制药公司包括 Novo Nordisk A/S、H. Lundbeck A/S、Leo Pharma A/S、Orifarm Group A/S、ALK-Abelló A/S、Xellia ApS、Takeda Pharma A/S , Sandoz A/S, Ferring Pharmaceuticals A/S 和 FUJIFILM Diosynth Biotechnologies

Novo Nordisk A/S Leo Pharma A/S H. Lundbeck A/S Orifarm Group A/S ALK-Abelló Nordic A / S

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions & Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

      1. 4.1.1 Healthcare Expenditure (Govt. Vs Private)

      2. 4.1.2 Pharmaceutical Imports and Exports

      3. 4.1.3 Epidemeology Data For key Diseases

      4. 4.1.4 Regulatory Landscape/Regulatory Bodies

      5. 4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)

      6. 4.1.6 Pipeline Analysis

        1. 4.1.6.1 By Phase

        2. 4.1.6.2 By Sponsor

        3. 4.1.6.3 By Disease

      7. 4.1.7 Statiscal Overview

        1. 4.1.7.1 Number of Hospitals

        2. 4.1.7.2 Employment in the Pharmaceutical Sector

        3. 4.1.7.3 R&D Expenditure

      8. 4.1.8 Ease of Doing Business

    2. 4.2 Market Drivers

      1. 4.2.1 Collaboration between Private and Public Sector

      2. 4.2.2 Rising Funding for Research and Development

    3. 4.3 Market Restraints

      1. 4.3.1 High Tax Rates on Pharmaceutical Products

      2. 4.3.2 Price-cap Agreements

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By ATC/Therapeutic Class (Both Value and Volume)

      1. 5.1.1 Alimentary Tract and Metabolism

      2. 5.1.2 Blood and Blood Forming Organs

      3. 5.1.3 Cardiovascular System

      4. 5.1.4 Dermatological Drugs

      5. 5.1.5 Genitourinary System and Reproductive Hormones

      6. 5.1.6 Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin

      7. 5.1.7 Antiinfectives for Systemic Use

      8. 5.1.8 Antineoplastic and Immunomodulating Agents

      9. 5.1.9 Musculoskeletal System

      10. 5.1.10 Nervous System

      11. 5.1.11 Antiparasitic Products, Insecticides and Repellents

      12. 5.1.12 Respiratory System

      13. 5.1.13 Sensory Organs

      14. 5.1.14 Various ATC Structures

    2. 5.2 By Sector

      1. 5.2.1 Primary Sector

      2. 5.2.2 Hospital Sector

    3. 5.3 By Prescription Type

      1. 5.3.1 Prescription Drugs (Rx)

      2. 5.3.2 OTC Drugs

  6. 6. COMPETITIVE LANDSCAPE & COMPANY PROFILES

    1. 6.1 Novo Nordisk A/S

    2. 6.2 H. Lundbeck A/S

    3. 6.3 Leo Pharma A/S

    4. 6.4 Orifarm Group A/S

    5. 6.5 ALK-Abell A/S

    6. 6.6 Xellia ApS

    7. 6.7 Takeda Pharma A/S

    8. 6.8 Sandoz A/S

    9. 6.9 Ferring Pharmaceuticals A/S

    10. 6.10 FUJIFILM Diosynth Biotechnologies

  7. 7. COMPANY SHARE ANALYSIS

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Denmark Pharmaceutical Market market is studied from 2018 - 2026.

The Denmark Pharmaceutical Market is growing at a CAGR of 3.4% over the next 5 years.

Novo Nordisk A/S, Leo Pharma A/S, H. Lundbeck A/S, Orifarm Group A/S, ALK-Abelló Nordic A / S are the major companies operating in Denmark Pharmaceutical Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!